ABSTRACT
Background Infantile hypertrophic pyloric stenosis (IHPS) is caused by hypertrophy of the pyloric sphincter smooth muscle. Building on a previously reported association between IHPS and lipid metabolism, we aimed to (1) investigate associations between IHPS and a wide array of lipid-centric targeted metabolites in newborns, and (2) address causality of the associations by integrating genetic data.
Methods Dried blood spots were taken from 267 pairs of IHPS cases and controls matched by sex and day of birth. A mixed effects linear regression model was used to evaluate associations between Biocrates p400 Kit selected 148 metabolites and IHPS in a matched case-control design.
Results Seven metabolites showed significantly lower levels in IHPS cases. Levels of the top associated metabolite, phosphatidylcholine PC(38:4), were significantly correlated with levels of the remaining six metabolites (P<2.30 ⨯ 10−12). Associations were driven by case-control pairs with older age at sampling. IHPS cases had more diagnoses for neonatal difficulty in feeding at breast (P = 6.15 ⨯ 10−3). Genetic variants explaining a large proportion of variance in the levels of PC(38:4) did not associate with IHPS.
Conclusions We detected lower levels of certain metabolites in IHPS, possibly reflecting different feeding patterns in the first days of life.
Key points
– Our previous GWAS of IHPS identified genetic associations between lipid metabolism and IHPS.
– Building on that finding, this study investigated associations between a wide array of lipid-centric metabolites in newborns and IHPS.
– Newborns who later developed IHPS had lower levels of certain metabolites. The associations were driven by individuals born at a later age at sampling, suggesting different feeding patterns after birth.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Novo Nordisk Foundation, Oak Foundation and Danish Research Council
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding source: This research was funded by the Danish Medical Research council (DFF 4004-00512) and Oak Foundation. It was conducted using the Danish National Biobank resource supported by the Novo Nordisk Foundation grant number 2010-11-12 and 2009-07-28.
Financial Disclosure: The authors have no financial relationships relevant to this article to disclose.
Conflict of Interest: The other authors have no potential conflicts of interest to disclose.
Data Availability
All data is available upon request.
